TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05837533

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication model
Description: During the medical consultation of each patient assigned to the intervention group, the oncologist will use the systematic communication model for patients with metastatic breast cancer. For this, the oncologist will follow the conversation guide for patients with metastatic breast cancer, which will allow directing the conversation towards information about the patient's diagnosis, treatment and prognosis. The guide consists of a series of steps and questions to be asked to the patient in order to explore her understanding of her disease and her information preferences, as well as to facilitate the oncologist providing said information to the patient. The responses to each item in the guide will be electronically documented by the oncologist.
Study: NCT05983185

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prism adaptation therapy
Description: The investigators' research and clinical group is the US leader in implementing this intervention for spatial neglect and have brought it to more than 50 clinical centers, hospitals, and treatment organizations.
Study: NCT05114967

Intervention type: OTHER
Intervention: mPAS questionnaire
Description: The modified Preoperative Anxiety Scale (mPAS) questionnaire as given in the article by Viola et al will be used after permission from the authors
Study: NCT05262738

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 50 Micrograms Vaginal Misoprostol (Intervention)
Description: Subjects will undergo cervical ripening with 50 micrograms of vaginal misoprostol every 4 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25 Micrograms Vaginal Misoprostol (Control)
Description: Subjects will undergo cervical ripening with 25 micrograms of vaginal misoprostol every 4 hours.
Study: NCT06309654

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 12-week home-based circuit training (HBCT)
Description: Participants in the exercise group performed HBCT three times per week on non-consecutive days for 12 weeks. The first session was conducted at USM Hospital and participants were instructed how to perform the prescribed exercises in a correct form. In each session, participants performed seven exercises (two aerobic- and five resistance-based) in a circuit fashion, using bodyweight movements and adjustable dumbbells for varied weights, activating all the major muscle groups. In weeks 1-6, participants executed 15 repetitions for 2 rounds with 1 min passive rest between exercises and rounds. In weeks 7-12, participants executed 30 repetitions for 4 rounds with the same rest as prescribed in weeks 1-6. Each round lasted 10-15 min and the total session duration was 20-60 min, aiming to help participants adapt gradually to increasing training volume.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Standard of care (CONT)
Description: Providing education about the nature of OA, its progression, and strategies for symptom management.~Empowering individuals with self-management techniques, such as joint protection strategies, activity modification, and lifestyle changes (e.g., weight management, exercise).
Study: NCT06581133

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Alarm system
Description: Generic alarm system programmed to sound during the night to try to induce arousals from sleep.
Study: NCT05438992

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Preservative-Free Injectable Solution
Description: local anesthetic drug injection for postoperative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Preservative-Free Injectable Solution
Description: local anesthetic drug injection for postoperative pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine 0.25% Preservative-Free Injectable Solution
Description: local anesthetic drug injection for postoperative pain
Study: NCT05049421

Intervention type: DIAGNOSTIC_TEST
Intervention: Echocardiography
Description: Full 2D and 3D echocardiography with special focus on right ventricular function
Study: NCT06130228

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Multi-ingredient supplement (PDT-MIS)
Description: Supplementation with active PDT-MIS daily

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (PLA)
Description: Supplementation with inactive placebo
Study: NCT05447260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: Dosage based on platelet count
Study: NCT05018013

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine hydrochloride enteric-coated tablets
Description: Ammoxetine hydrochloride enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine hydrochloride enteric-coated tablets
Description: Ammoxetine hydrochloride enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine hydrochloride enteric-coated tablets
Description: Ammoxetine hydrochloride enteric-coated tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ammoxetine hydrochloride enteric-coated tablets
Description: Ammoxetine hydrochloride enteric-coated tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Duloxetine hydrochloride enteric-coated capsules
Description: Duloxetine hydrochloride enteric-coated capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Ammoxetine
Description: Placebo to Ammoxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Ammoxetine
Description: Placebo to Ammoxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Duloxetine
Description: Placebo to Duloxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Duloxetine
Description: Placebo to Duloxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Duloxetine
Description: Placebo to Duloxetine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Duloxetine
Description: Placebo to Duloxetine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Duloxetine
Description: Placebo to Duloxetine
Study: NCT04576975

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline 0.9%
Description: compare the use of ketamine versus dexmedetomidine when used as perioperative infusion in obese patients undergoing laparoscopic bariatric surgery regarding their analgesic efficacy as well as any side effects or drawbacks (PONV and effects on consciousness) that might associate with their use.
Study: NCT06464224

Intervention type: BEHAVIORAL
Intervention: low respiratory effort
Description: patients under respiratory effort lower than -1,5 cmH2O (P0,1) and/or -7 cmH2O (Pocc)

Intervention type: BEHAVIORAL
Intervention: high respiratory effort
Description: patients under respiratory effort higher than -3,5 cmH2O (P0,1) and/or -15 cmH2O (Pocc)
Study: NCT06514417

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: US-guided external oblique intercostal block
Description: After induction of general anesthesia, external oblique intercostal block will be performed (8) under ultrasonographic guidance with transportable ultrasound device ( Sonosite ,superficial probe ,14-15 MHz).~the patient will be positioned supine, and a linear ultrasound transducer will be placed in the sagittal plane between the midclavicular and anterior axillary lines at the level of sixth rib. 20 ml of bupivacaine 0.25% will be injected between the plane of the external oblique and the intercostal muscles. The drug will be injected after a negative aspiration.~The contralateral side block will be performed in a same manner.
Study: NCT05719688

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mechanical thrombectomy
Description: Treatment of ischemic stroke patients with Mechanical thrombectomy

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mechanical thrombectomy
Description: Treatment of ischemic stroke patients with Mechanical thrombectomy
Study: NCT05567146

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental group
Description: It is planned to use the social media platform WhatsApp application to carry out the study. technique of gamification will have content in the form of points, ranking, penalties and rewards, which are the basic principles of gamification.~Studies have shown that these contents are effective techniques to increase the interest, encouragement, motivation and purpose of the participants.
Study: NCT04798612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegasys
Description: 45 mikrograms of Pegasys. Two subcutanous doses will be administered with at least 7 days in between

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: 0.50 ml of Saline. Two subcutanous doses will be administered with at least 7 days in between
Study: NCT06008366

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7MW3711 for injection
Description: IV administration of 7MW3711, Q3W, 3 weeks a cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7MW3711 for injection
Description: IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
Study: NCT05445661

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: injectable poly-L-lactic acid
Description: Injectable biostimulant for volume loss

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Normal Saline
Description: Sham Comparator
Study: NCT05128968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endotracheal intubation
Description: Endotracheal intubation is performed in simple head extension or sniffing position using a McGrath MAC videolaryngoscope.
Study: NCT05178433

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Use baby moisturizers by NeoChine
Description: During continuous phototherapy, use skin basic care and protection in combination with baby moisturizing products, use the whole body twice a day, and the amount of each time is not less than 5 grams.
Study: NCT00476983

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: saquinavir/ritonavir plus truvada
Description: SQV/r 1500/100 mg OD + Truvada OD for 2 years
Study: NCT04721444

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification of parenchymal lung change cause
Description: Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification of parenchymal lung change cause
Description: Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification of parenchymal lung change cause
Description: Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification of parenchymal lung change cause
Description: Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification of parenchymal lung change cause
Description: Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification of parenchymal lung change cause
Description: Arms A \& B: Radiomics and deep-learning approaches will be used on patient's imaging to develop a feature vector that can distinguish parenchymal lung changes, e.g. infection from drug-toxicity.

Intervention type: DIAGNOSTIC_TEST
Intervention: Machine Learning Classification of recurrence and non-recurrence
Description: Arm C: Radiomics and deep-learning approaches will be used on patient's imaging to develop a risk-signature for recurrence of malignancy following radical treatment
Study: NCT04849065

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MNC (Mononuclear cells)
Description: * Intramuscular infusion of autologous BM CMN into the TA muscle of one of the lower limbs (experimental side)~* Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo / Saline
Description: - Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo / Saline
Description: - Intramuscular infusion of saline solution (placebo) in the TA muscle of the contralateral lower limb (control side)
Study: NCT05189886

Intervention type: PROCEDURE
Intervention: Double Balloon Valvuloplasty in TAVR
Description: The prospective phase will enroll patients planning to undergo TAVR, at the discretion of Drs. Wan and Fatemi, and if they meet all of the inclusion criteria and none of the exclusion criteria. All patients who provide consent will undergo the TAVR procedure where the valve will be double inflated. Echocardiogram results and procedure details will be collected as data. At the patient's 30-day follow-up clinic visit, as per standard of care, they will be re-evaluated with an echocardiogram. Details from that follow-up visit and the echocardiogram results will be collected as data. Prospective enrollment will begin upon IRB approval and we plan to continue enrollment until December 31, 2023, or once 200 participants are reached, whichever comes first.
Study: NCT05962203

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Multi-factorial geriatric assessment, monitoring & management systems
Description: Multi-factorial geriatric assessment, monitoring \& management systems, e.g. community-based and home-based exercise programs, polypharmacy
Study: NCT05503810

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social support
Description: Contact ones a week with Informal caregiver or peer support
Study: NCT06361979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR-A1811
Description: SHR-A1811: intravenous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab:intravenous
Study: NCT05387044

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SBRT
Description: Patients with oligoprogressive NSCLC after first line treatment with immune checkpoint inhibitors will be treated with SBRT for all progressing lesions.
Study: NCT04934410

Intervention type: DRUG
Intervention: Etomidate
Description: Use of etomidate during induction as decided by attending anesthesiologist

Intervention type: DRUG
Intervention: Midazolam
Description: Use of midazolam during induction as decided by attending anesthesiologist

Intervention type: DRUG
Intervention: Sevoflurane
Description: Use of sevoflurane during induction as decided by attending anesthesiologist
Study: NCT06370130

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 0.2mg/kg
Description: Patients received 0.2 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esketamine 0.3mg/kg
Description: Patients received 0.3 mg/kg of esketamine intravenously for 30 s，after 120 s of propofol and disappearance of the eyelash reflex, a laryngeal mask was inserted.~The test was performed using the sequential method. The initial dose of propofol was 2 mg/kg, which can be easily inserted into the LMA, and the propofol dose ratio of the adjacent patient was 0.9. If there was a positive reaction to the LMA insertion, the gradient was increased for the next patient; otherwise, the gradient was decreased, and the study was terminated after seven crossover inflection points.
Study: NCT04735757

Intervention type: OTHER
Intervention: Contrast-enhanced MRI
Description: Contrast-enhanced MRI

Intervention type: OTHER
Intervention: Contrast-enhanced MRI
Description: Contrast-enhanced MRI

Intervention type: OTHER
Intervention: Contrast-enhanced MRI
Description: Contrast-enhanced MRI

Intervention type: OTHER
Intervention: Measurement of respiratory muscle force
Description: Measurement of the maximum inspiratory and expiratory pressure.

Intervention type: OTHER
Intervention: Measurement of respiratory muscle force
Description: Measurement of the maximum inspiratory and expiratory pressure.

Intervention type: OTHER
Intervention: Measurement of respiratory muscle force
Description: Measurement of the maximum inspiratory and expiratory pressure.
Study: NCT04623567

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Jiangtang Tiaozhi recipe
Description: The Jiangtang Tiaozhi recipe is a combination of several Chinese herbs, which has been granted a patent (No. ZL 2013 1 0373659.7)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: The metformin tablets (500mg) will be administrated.
Study: NCT05126355

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: On the Move group exercise
Description: The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: On the Move group exercise
Description: The OTM exercise program is a group-based program led by a certified OTM instructor. The frequency and duration of OTM is 50 minutes, twice weekly for 12 weeks for a total of 24 classes. The OTM exercise program is based on principles of motor learning that enhance smooth and automatic movement control. The program contains a warm-up (5 minutes), stepping patterns (15 minutes), walking patterns (15 minutes), strengthening exercises (10 minutes), and cool-down exercises (5 minutes). The warm-up and cool down contain gentle range of motion exercises and stretches for the lower extremities and trunk. Considered essential components, the stepping and walking patterns are progressively more difficult, goal-oriented patterns that promote the timing and coordination of stepping integrated with the phases of the gait cycle.
Study: NCT06351436

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: The mindfulness-based intervention will last for three months, with 6-8 weekly sessions lasting 1.5 hours each. Participants will attend the sessions in a group format, and the sessions will be administered by registered social worker who are specialized in counseling. The intervention is delivered using an immersive virtual reality cave system. The intervention content is designed by a registered clinical psychologist accredited for delivering mindfulness-based intervention and nurses who are experienced in mindfulness training. To ensure protocol adherence, the social workers administering the intervention will receive close supervision from the clinical psychologist. Weekly meetings will be held to discuss and resolve any difficulties or challenges encountered by the social workers.
Study: NCT05974436

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and dialysate sampling
Description: Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and dialysate sampling
Description: Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood and dialysate sampling
Description: Blood is sampled from the inlet and outlet dialyzer bloodline at 5min after dialysis start.~Spent dialysate is sampled from the outlet dialysate line at 5, 30, 90 and 240min after dialysis start.~Blood and dialysate samples are analysed for different uremic toxins. Dialysis efficiency is calculated from the analysed toxin concentrations.